Sonpavde Guru, Hutson Thomas E, Berry William R
US Oncology Research Network Houston, TX, USA.
Cancer Treat Rev. 2006 Apr;32(2):90-100. doi: 10.1016/j.ctrv.2005.12.005. Epub 2006 Feb 3.
Effective therapeutic options have not existed for prostate cancer progressing after androgen deprivation therapy until very recently. Secondary hormonal manipulations offer marginal benefits. Docetaxel based chemotherapy has been demonstrated to extend survival and change the natural history of the disease in two large randomized trials. These studies have provided the impetus to combine docetaxel with novel biologic agents to further consolidate the gains in long-term outcome. With the arrival of exciting agents including vaccines, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, anti-angiogenic drugs and small molecule receptor tyrosine kinase inhibitors, the future treatment of prostate cancer appears promising.
直到最近，对于雄激素剥夺治疗后进展的前列腺癌，还不存在有效的治疗选择。二次激素治疗带来的益处微乎其微。两项大型随机试验已证明，基于多西他赛的化疗可延长生存期并改变疾病的自然病程。这些研究推动了将多西他赛与新型生物制剂联合使用，以进一步巩固长期治疗效果的提升。随着包括疫苗、单克隆抗体、骨靶向药物、反义寡核苷酸、抗血管生成药物和小分子受体酪氨酸激酶抑制剂等令人振奋的药物的出现，前列腺癌的未来治疗前景似乎很乐观。
Zotero 插件